Because it matters.

Accelerating the journey from data to medicine.


More Effective Drugs.


BenevolentAI is creating and applying AI technologies to transform the way medicines are discovered, developed, tested and brought to market.  The Company has developed the Benevolent Platform™ - a leading computational and experimental discovery platform used by BenevolentAI scientists to find new ways to treat disease and personalise drugs to patients.

The Benevolent Platform™ focuses on four key areas of drug discovery and development: Knowledge and Reasoning, Target Identification, Molecular Design and Precision Medicine


For every patient.

I work here because I want to transform drug discovery to serve every patient equally. I want to develop AI that benefits society
— Alix. VP Data Science, New York
Alix Lacoste.jpg

Better Data Decision Making.


BenevolentAI seeks to improve patient’s lives by applying technology designed to generate better data decision making and in doing so lower drug development costs, decrease failure rates and increase the speed at which medicines are generated.  


Where it happens.



We're headquartered in London’s ‘Knowledge Quarter,’ where our neighbours include Google, Facebook, the Alan Turing Institute, the Francis Crick Institute, UCL and the Wellcome Trust.


We operate our own state-of-the-art BenevolentAI drug discovery and development facility, on the world famous Babraham Research Campus, Cambridge UK.

New York

Our New York office opened in 2017 and looks out onto the Brooklyn Bridge. The team is twenty-strong and growing, and works side-by-side within squads that span all our locations.


We have a small but perfectly formed team of engineers in Antwerp, Belgium, led by Benevolent's SVP Technology.


Lately at BenevolentAI.



AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery

Collaboration with BenevolentAI will use machine learning and artificial intelligence to discover potential new drugs for chronic kidney disease and idiopathic pulmonary fibrosis. AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

AstraZeneca BenevolentAI